- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06168734
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP (CERTAIN-2)
April 22, 2024 updated by: Venatorx Pharmaceuticals, Inc.
A Phase 3 Study to Evaluate Cefepime-taniborbactam Compared to Meropenem in Adults With Ventilator Associated Bacterial Pneumonia (VABP) or Ventilated Hospital Acquired Bacterial Pneumonia (vHABP)
This is a Phase 3, randomized, multicenter, double-blind, non-inferiority study to evaluate the efficacy and safety of cefepime-taniborbactam compared to meropenem in patients ≥ 18 years of age with ventilated HABP or VABP.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
316
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Venatorx
- Phone Number: 610-644-8935
- Email: vnrxclinsci@venatorx.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female, ≥18 years of age.
- The patient or patient's legally authorized/acceptable representative (LAR) has voluntarily signed and dated the IRB/IEC approved ICF
- Meets the clinical diagnosis of ventilated HABP or VABP
Have at least one of the following clinical criteria:
- New onset or worsening of pulmonary symptoms and signs
- New onset or worsening of purulent respiratory secretions
- Hypoxemia
- Need for acute changes in ventilator support
Have at least one of the following clinical criteria:
- Documented fever (defined as body temperature ≥ 38°C [100.4°F]
- Hypothermia (defined as body temperature ≤ 35°C [95°F])
- White blood cell (WBC) ≥10,000 cells/mm3 or ≤4,500 cells/mm3
- >15% immature neutrophils (bands).
- Have new or worsening infiltrate on a pulmonary imaging study that is consistent with bacterial pneumonia within 48 hours prior to randomization.
- Have a lower respiratory tract specimen sent for Gram stain and quantitative culture within 36 hours prior to the first dose of study drug.
Exclusion Criteria:
- Receipt of effective antibacterial treatment for pneumonia for a continuous duration of >24 hours during the previous 72 hours prior to randomization.
Pneumonia known or suspected to be caused by:
- A bacterial pathogen resistant to meropenem, as assessed by susceptibility testing or against which either one or both study drugs lack activity
- Viruses, atypical bacteria, or fungi
- Use of non-study systemic gram-negative therapy.
- Confounding respiratory conditions.
- Receiving extracorporeal membrane oxygenation (ECMO).
- Patients with refractory septic shock.
- Active immunosuppression.
- Has a history of serious hypersensitivity (e.g., anaphylaxis), serious allergy, or any serious reaction to cephalosporin, penicillin, carbapenem, or other β-lactam antibiotics.
- Female patients who are pregnant.
- Patients with eGFR <10 mL/min/1.73 m2 or are receiving or starting renal replacement therapy or expected to require renal replacement therapy during the treatment phase of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cefepime-taniborbactam
cefepime-taniborbactam (2g/0.5g)
IV every 8 hours.
|
Cefepime-taniborbactam administered 2.5g q8h intravenously (IV) over a 4-hour period for 7 days to 14 days at the investigator's discretion.
Dose adjustments for renal function may apply.
|
Active Comparator: Meropenem
Comparator: meropenem (2g) IV every 8 hours.
|
Meropenem will be administered 2g q8h IV over 4 hours for 7 days to 14 days at the investigator's discretion.
Dose adjustments for renal function may apply.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ACM through Study Day 14
Time Frame: Evaluated on Day 15
|
The primary endpoint is ACM, a binary variable, through Study Day 14.
The primary endpoint is evaluated in the ITT population and is based on the patient's survival status through Study Day 14.
|
Evaluated on Day 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ACM through Study Day 28
Time Frame: Evaluated on Day 29-33
|
ACM through Study Day 28; analyzed in ITT and MITT analysis populations.
|
Evaluated on Day 29-33
|
Safety Outcomes
Time Frame: From first dose up to Day 33
|
Safety assessments include the incidence of TEAEs and SAEs, and discontinuation of study drug due to TEAEs.
|
From first dose up to Day 33
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Carlos Fernando de Oliveira, MD, PhD, MSc, Venatorx Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2024
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
September 1, 2027
Study Registration Dates
First Submitted
December 4, 2023
First Submitted That Met QC Criteria
December 4, 2023
First Posted (Actual)
December 13, 2023
Study Record Updates
Last Update Posted (Actual)
April 24, 2024
Last Update Submitted That Met QC Criteria
April 22, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Disease Attributes
- Bacterial Infections
- Bacterial Infections and Mycoses
- Cross Infection
- Iatrogenic Disease
- Healthcare-Associated Pneumonia
- Pneumonia
- Pneumonia, Bacterial
- Pneumonia, Ventilator-Associated
- Anti-Infective Agents
- Anti-Bacterial Agents
- Meropenem
- Cefepime
Other Study ID Numbers
- VNRX-5133-301
- 2022-502682-16 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hospital-acquired Pneumonia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Basilea PharmaceuticaCompletedCommunity-acquired Pneumonia (CAP) | Hospital-acquired Pneumonia (HAP)Bulgaria, Hungary, Georgia, Romania
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
Liverpool University Hospitals NHS Foundation TrustLiverpool School of Tropical MedicineCompletedCommunity Acquired Pneumonia | Lower Respiratory Tract Infection | Hospital Acquired PneumoniaUnited Kingdom
-
University Hospital OlomoucPalacky UniversityCompletedHospital Acquired Pneumonia
-
PfizerCompletedHospital-Acquired PneumoniaChina
-
University of BirminghamHeart of England NHS TrustCompletedHospital Acquired PneumoniaUnited Kingdom
-
Nantes University HospitalNot yet recruitingHospital Acquired PneumoniaFrance
-
Assiut UniversityUnknownPneumonia Hospital AcquiredEgypt
-
PfizerRecruitingHospital Acquired Pneumonia | Complicated Intra Abdominal Infections | Ventilator Acquired PneumoniaChina
Clinical Trials on Cefepime-taniborbactam
-
Venatorx Pharmaceuticals, Inc.CompletedHealthy SubjectsUnited States
-
Venatorx Pharmaceuticals, Inc.CompletedUrinary Tract Infections | Acute PyelonephritisUnited States, Argentina, Brazil, Bulgaria, China, Croatia, Hungary, Latvia, Mexico, Peru, Romania, Russian Federation, Serbia, Turkey, Ukraine
-
Hospital de Clinicas de Porto AlegreUnknownUrinary Tract Infection | Respiratory Tract InfectionBrazil
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | Breast Cancer | Primary Myelofibrosis | Multiple Myeloma | Ovarian Epithelial Cancer | Chronic Myelomonocytic Leukemia | Neutropenia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone... and other conditionsUnited States
-
AllecraMedpace, Inc.CompletedUrinary Tract InfectionsHungary, Czechia, Poland, Slovakia, Ukraine
-
WockhardtMedpace, Inc.RecruitingAcute Pyelonephritis | Complicated Urinary Tract InfectionUnited States, China, India, Lithuania, Mexico, Peru, Poland, Bulgaria, Estonia
-
AllecraCompleted
-
Venatorx Pharmaceuticals, Inc.National Institutes of Health (NIH)CompletedHealthy SubjectsUnited States
-
CPL AssociatesElan PharmaceuticalsCompleted
-
Hospital Authority, Hong KongCompleted